Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 9/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23113052 | 0.94 | AHR (0.38) | AHRMAP3K5GAANPC1RAB9A | |
| SCHEMBL30385381 | 0.81 | — | — | |
| SCHEMBL20472412 | 0.81 | AHR (0.41) | AHRSOS1BACE1MAPT | |
| SCHEMBL23693424 | 0.77 | BACE1 (0.43) | BACE1 | |
| SCHEMBL25440181 | 0.76 | AHR (0.39) | AHRSOS1BACE1 | |
| SCHEMBL31489814 | 0.76 | PIK3CG (0.38) | TTKPIK3CG | |
| SCHEMBL3302386 | 0.74 | SSTR4 (0.37) | — | |
| SCHEMBL3300667 | 0.74 | AHR (0.39) | AHR | |
| SCHEMBL12093489 | 0.74 | AHR (0.39) | AHRNPC1RAB9A | |
| SCHEMBL31489352 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307515-A | Antibacterial compounds | 英菲克斯治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11845725-B2 | Antibacterial compounds | Infex Therapeutics Limited (GB) | 2023-12-19 | — | — | US | disclosed |
| EP-3793990-B1 | ANTIBACTERIAL COMPOUNDS | INFEX THERAPEUTICS LTD (GB) | 2023-07-19 | — | — | EP | disclosed |
| US-20230060011-A1 | ANTIBACTERIAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2023-02-23 | — | — | US | disclosed |
| US-11459296-B2 | Antibacterial compounds | Infex Therapeutics Limited (GB) | 2022-10-04 | — | — | US | disclosed |
| US-20210230115-A1 | Antibacterial Compounds | Infex Therapeutics Limited (GB) | 2021-07-29 | — | — | US | disclosed |
| EP-3793990-A1 | ANTIBACTERIAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2021-03-24 | — | — | EP | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2640366-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068096-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | AHR 2791/4885MAP3K5 153/4885GAA 752/4885 |
| US-20230060011-A1 | ANTIBACTERIAL COMPOUNDS | GAA, MGAM, NQO1 | AHR 3921/4885MAP3K5 2414/4885GAA 1/4885 |
| US-20210230115-A1 | Antibacterial Compounds | GAA, MGAM, NQO1 | AHR 3921/4885MAP3K5 2414/4885GAA 1/4885 |
| US-11459296-B2 | Antibacterial compounds | GAA, MGAM, NQO1 | AHR 3921/4885MAP3K5 2414/4885GAA 1/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | AHR 2849/4885MAP3K5 125/4885GAA 686/4885 |
| US-11845725-B2 | Antibacterial compounds | GAA, MGAM, NQO1 | AHR 3921/4885MAP3K5 2414/4885GAA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.